RSV LID/ΔM2-2/1030s(RSV LID/ΔM2-2/1030s) - 在研适应症：呼吸道合胞体病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染

在研适应症

呼吸道合胞体病毒感染

非在研适应症-

原研机构

National Institute of Allergy & Infectious Diseases

在研机构

National Institute of Allergy & Infectious Diseases

Sanofi Pasteur SA

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 RSV LID/ΔM2-2/1030s 相关的临床试验

NCT04520659

/ Completed临床1期IIT

Phase Ib Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.

开始日期2022-03-16

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+1]

NCT02952339

/ Completed临床1期IIT

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age

The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants 6 to 24 months of age.
This study is a companion study to IMPAACT 2011.

开始日期2016-08-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT02794870

/ Completed临床1期IIT

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

The purpose of this study was to evaluate the safety, infectivity, and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants 6 to 24 months of age.
This study was a companion study to CIR 311.

开始日期2016-07-15

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 RSV LID/ΔM2-2/1030s 相关的临床结果

登录后查看更多信息

100 项与 RSV LID/ΔM2-2/1030s 相关的转化医学

登录后查看更多信息

100 项与 RSV LID/ΔM2-2/1030s 相关的专利（医药）

登录后查看更多信息

100 项与 RSV LID/ΔM2-2/1030s 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道合胞体病毒感染	临床1期	美国	National Institute of Allergy & Infectious Diseases	2016-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02794870 (CTgov)	临床1期	呼吸道合胞体病毒感染	33	RSV LID ΔM2-2 1030s vaccine (RSV LID ΔM2-2 1030s Vaccine)	願網遞廠築鹽製憲膚襯 = 壓積繭積夢鹹壓蓋膚廠願壓醖齋願艱憲鬱製觸 (顧網餘網糧構顧夢鏇淵, 遞鑰糧製範齋鑰築淵齋 ~ 鑰窪壓鏇觸壓築遞蓋鹽) 更多	-	2018-08-27
				Placebo (Placebo)	願網遞廠築鹽製憲膚襯 = 艱窪遞糧廠憲積夢鹽廠願壓醖齋願艱憲鬱製觸 (顧網餘網糧構顧夢鏇淵, 憲餘繭艱壓憲繭鹹蓋衊 ~ 鑰衊願夢範遞憲鹹鹽網) 更多